174 related articles for article (PubMed ID: 19351753)
1. G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis.
Stein CA; Wu S; Voskresenskiy AM; Zhou JF; Shin J; Miller P; Souleimanian N; Benimetskaya L
Clin Cancer Res; 2009 Apr; 15(8):2797-807. PubMed ID: 19351753
[TBL] [Abstract][Full Text] [Related]
2. Comparison of d-g3139 and its enantiomer L-g3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency.
Lai JC; Brown BD; Voskresenskiy AM; Vonhoff S; Klussman S; Tan W; Colombini M; Weeratna R; Miller P; Benimetskaya L; Stein CA
Mol Ther; 2007 Feb; 15(2):270-8. PubMed ID: 17235304
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
[TBL] [Abstract][Full Text] [Related]
5. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
[TBL] [Abstract][Full Text] [Related]
6. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature.
Anderson EM; Miller P; Ilsley D; Marshall W; Khvorova A; Stein CA; Benimetskaya L
Cancer Gene Ther; 2006 Apr; 13(4):406-14. PubMed ID: 16195754
[TBL] [Abstract][Full Text] [Related]
7. Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
Benimetskaya L; Lai JC; Khvorova A; Wu S; Hua E; Miller P; Zhang LM; Stein CA
Clin Cancer Res; 2004 Dec; 10(24):8371-9. PubMed ID: 15623615
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis by G3139 in melanoma cells.
Benimetskaya L; Lai JC; Khvorova A; Wu S; Miller P; Stein CA
Ann N Y Acad Sci; 2005 Nov; 1058():235-45. PubMed ID: 16394140
[TBL] [Abstract][Full Text] [Related]
9. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
[TBL] [Abstract][Full Text] [Related]
10. Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells.
Lefèvre G; Babchia N; Calipel A; Mouriaux F; Faussat AM; Mrzyk S; Mascarelli F
Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1047-57. PubMed ID: 19029025
[TBL] [Abstract][Full Text] [Related]
11. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner.
Lai JC; Benimetskaya L; Santella RM; Wang Q; Miller PS; Stein CA
Mol Cancer Ther; 2003 Oct; 2(10):1031-43. PubMed ID: 14578468
[TBL] [Abstract][Full Text] [Related]
12. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).
Raffo A; Lai JC; Stein CA; Miller P; Scaringe S; Khvorova A; Benimetskaya L
Clin Cancer Res; 2004 May; 10(9):3195-206. PubMed ID: 15131061
[TBL] [Abstract][Full Text] [Related]
13. Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.
Lai JC; Benimetskaya L; Khvorova A; Wu S; Hua E; Miller P; Stein CA
Mol Cancer Ther; 2005 Feb; 4(2):305-15. PubMed ID: 15713901
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease.
Benimetskaya L; Wu S; Voskresenskiy AM; Echart C; Zhou JF; Shin J; Iacobelli M; Richardson P; Ayyanar K; Stein CA
Blood; 2008 Nov; 112(10):4343-52. PubMed ID: 18711003
[TBL] [Abstract][Full Text] [Related]
15. Heterodimerization of FGF-receptor 1 and PDGF-receptor-alpha: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells.
Faraone D; Aguzzi MS; Ragone G; Russo K; Capogrossi MC; Facchiano A
Blood; 2006 Mar; 107(5):1896-902. PubMed ID: 16322476
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
[TBL] [Abstract][Full Text] [Related]
17. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
Dai G; Chan KK; Liu S; Hoyt D; Whitman S; Klisovic M; Shen T; Caligiuri MA; Byrd J; Grever M; Marcucci G
Clin Cancer Res; 2005 Apr; 11(8):2998-3008. PubMed ID: 15837754
[TBL] [Abstract][Full Text] [Related]
18. Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo.
Ma Y; Zhao W; Li Y; Pan Y; Wang S; Zhu Y; Kong L; Guan Z; Wang J; Zhang L; Yang Z
Biomaterials; 2019 Mar; 197():182-193. PubMed ID: 30660994
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
Lopes de Menezes DE; Hu Y; Mayer LD
J Exp Ther Oncol; 2003; 3(2):72-82. PubMed ID: 12822513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
